Dietary caffeine as a probe agent for assessment of cytochrome P4501A2 activity in random urine samples

British Journal of Clinical Pharmacology

Volumn 47, Issue 4, 1999, Pages 397-402

  Nordmark, Anna ^a   Lundgren, Stefan ^a   Cnattingius, Sven ^b   Rane, Anders ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

CYP1A2 activity; Dietary caffeine; Metabolic ratio; Phenotyping; Validation

Indexed keywords

CAFFEINE; PHENACETIN O DEETHYLASE;

ARTICLE; DIAGNOSTIC ACCURACY; DIETARY INTAKE; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; METABOLITE; NORMAL HUMAN; PREGNANCY; PRIORITY JOURNAL; SMOKING HABIT; URINALYSIS; URINE;

CAFFEINE; CYTOCHROME P-450 CYP1A2; DIET; FEMALE; HUMANS; MALE; PHENOTYPE;

EID: 0032904618     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00918.x     Document Type: Article

References (27)

1. 1 Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich PF. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes from 30 japanese and 30 caucasians. J Pharmacol Exp Ther 1994; 270: 414-423.
2. 2 Campbell ME, Grant DM, Inaba T, Kalow W. Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) in human liver microsomes. Drug Metab Dispos 1987; 15: 237-249.
3. 3 Gu L, Gonzalez FJ, Kalow W, Tang BK. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics 1992; 2: 73-77.
4. 4 Jerling M, Lindstrom L, Bondesson U, Bertilsson L. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monitor 1994; 16: 368-374.
5. 5 Bertilsson L, Carillo JA, Dahl M-L, et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 1994; 38: 471-473.
6. 6 Lemoine A, Gautier JC, Azoulay D, et al. Major pathway of imipramine metabolism is catalysed by cytochromes P-450 1A2 and P 450 3A4 in human liver. Mol Pharmacol 1993; 43: 827-832.
7. 7 Berthou F, Flinois JP, Ratanasavanh D, Beanu P, Riche C, Guillouz A. Evidence for the involvement of several cytochromes P450 in the first steps of caffeine metabolism by human liver microsomes. Drug Metab Disp 1991; 19: 561-567.
8. 8 Eaton DL, Gallagher EP, Bammler TK, Kunze KL. Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability and enzyme activity. Pharmacogenetics 1995; 5: 259-274.
9. 9 Tassaneeyakul W, Mohamed Z, Birkett DJ, et al. Caffeine as a probe for human cytochromes P450: validation using cDNA-expression, immunoinhibition and microsomal kinetic and inhibitor techniques. Pharmacogenetics 1992; 2: 173-183.
10. 10 Campbell ME, Spielberg SP, Kalow W. A urinary metabolite ratio that reflects systemic caffeine clearance. Clin Pharmacol Ther 1987; 42: 157-165.
11. 11 Denaro CP, Wilson W, Jacob III P, Benowitz NL. Validation of urine caffeine metabolite ratios with use of stable isotope labeled caffeine clearance. Clin Pharmacol Ther 1996; 59: 284-296.
12. 12 Rost KL, Roots I. Accelerated caffeine metabolism after ompeprazole treatment is indicated by urinary metabolite ratios: Coincidence with plasma clearance and breath test. Clin Pharmacol Ther 1994; 55: 402-411.
13. 13 Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-149.
14. 14 Kalow W, Tang B-K. Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities. Clin Pharmacol Ther 1991; 50: 508-519.
15. 15 Kalow W, Tang B-K. Caffeine as a metabolic probe: Exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 1991; 49; 44-48.
16. 16 Vistisen K, Poulsen HE, Loft S. Foreign compound metabolism capacity in man measured from metabolites of dietary caffeine. Carcinogenesis 1992; 13: 1561-1568.
17. 17 Rasmussen BB, Brosen K. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase and N-acetyltransferase activity in humans. Ther Drug Monit 1996; 18: 254-262.
18. 18 Lelo A, Miners JO, Robson R, Birkett DJ. Assessment of caffeine exposure: Caffeine content of beverages, caffeine intake, and plasma concentration of methylxanthines. Clin Pharmacol Ther 1986; 39: 54-59.
19. 19 Ayalogu E, Snelling J, Lewis DFV, Talwar S, Clifford M, Ioannides C. Induction of hepatic CYP1A2 by the oral administration of caffeine to rats; lack of association with the Ah locus. Biochim Biophys Acta 1995; 1272: 89-94.
20. 20 Goasduff T, Dréano Y, Guillois B, Ménez J F, Berthou F. Induction of liver and kidney CYP1A1/1A2 by caffeine in rat. Biochem Pharmacol 1996; 52: 1915-1919.
21. 21 Chen L, Bondoc FY, Lee M J, Hussin AH, Thomas PE, Yang CS. Caffeine induces cytochrome P4501A2: induction of CYP1A2 by tea in rats. Drug Metab Dispos 1996; 24: 529-533.
22. 22 Kalow W, Tang BK. The use of caffeine for enzyme assays; A critical appraisal. Clin Pharmacol Ther 1993; 53: 503-514.
23. 23 Schrenk D, Brockmeier D, Mörike K, Bock KW, Eichelbaum M. A distribution study of CYP1A2 phenotypes among smokers and non-smokers in a cohort of healthy Caucasian volunteers. Eur J Clin Pharmacol 1998; 53: 361-367.
24. 24 Denaro CP, Brown CR, Wilson M, Jacob III P, Benowitz NL. Dose dependency of caffeine metabolism with repeated dosing. Clin Pharmacol Ther 1990; 48: 277-285.
25. 25 Cheng WS, Murhy TL, Smith MT, Cooksley WG, Halliday JW, Powell LW. Dose-dependent pharmarokinetics of caffeine in humans: relevance as a test of quantitative liver function. Clin Pharmacol Ther 1990; 47: 516-524.
26. 26 Kashuba ADM, Bertino JS, Kearns GL, et al. Quantitation of three-month intraindividual variability and influence of sex and menstrual cycle phase on CYP1A2, N-acetyltransferase-2, and xanthine oxidase activity determined with caffeine phenotyping. Clin Pharmacol Ther 1998; 63: 540-551.
27. 27 Parsons WD, Neims AH. Effect of smoking on caffeine clearance. Clin Pharmacol Ther 1978; 24: 40-45.